Bio-Rad Laboratories, Inc. Class B

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell BIO.B and other ETFs, options, and stocks.

About BIO.B

Bio-Rad Laboratories, Inc. engages in the development, manufacturing, and marketing of a portfolio of instruments, systems, reagents, and consumables. It operates through the following segments: Life Science and Clinical Diagnostics. 

CEO
Norman D. Schwartz
CEONorman D. Schwartz
Employees
7,450
Employees7,450
Headquarters
Hercules, California
HeadquartersHercules, California
Founded
1952
Founded1952
Employees
7,450
Employees7,450

BIO.B Key Statistics

Market cap
8.28B
Market cap8.28B
Price-Earnings ratio
51.39
Price-Earnings ratio51.39
Dividend yield
Dividend yield
Average volume
52.12
Average volume52.12
High today
High today
Low today
Low today
Open price
Open price
Volume
0.00
Volume0.00
52 Week high
$321.12
52 Week high$321.12
52 Week low
$244.54
52 Week low$244.54

Stock Snapshot

Bio-Rad Laboratories, Inc. Class B(BIO.B) stock is priced at $309.37, giving the company a market capitalization of 8.28B. It carries a P/E multiple of 51.39.

On 2026-07-22, Bio-Rad Laboratories, Inc. Class B(BIO.B) shares started trading at —, with intraday highs of — and lows of —.

Trading activity shows a volume of 0, compared to an average daily volume of 52.12.

The stock's 52-week range extends from a low of $244.54 to a high of $321.12.

The stock's 52-week range extends from a low of $244.54 to a high of $321.12.

BIO.B News

Simply Wall St 12h
Bio Rad Laboratories Stock Looks Fairly Valued After A 57% Slide

Bio-Rad Laboratories has produced a mixed experience for long term shareholders, with the stock down about 57.1% over five years, yet recent trading leaves it l...

Bio Rad Laboratories Stock Looks Fairly Valued After A 57% Slide
TipRanks 1d
Bio-Rad slips as Sartorius weighed on by Danaher bioprocessing unit miss

Sartorius (SSSGY) shares are trading lower in Europe after earnings from competitor Danaher (DHR), including bioprocessing unit results that missed expectations...

Analyst ratings

50%

of 6 ratings
Buy
33.3%
Hold
50%
Sell
16.7%

People also own

Based on the portfolios of people who own BIO.B. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.